230 related articles for article (PubMed ID: 24240815)
41. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
Cirac A; Stützle S; Dieckmeyer M; Adhikary D; Moosmann A; Körber N; Bauer T; Witter K; Delecluse HJ; Behrends U; Mautner J
Cancer Immunol Immunother; 2018 Apr; 67(4):663-674. PubMed ID: 29374782
[TBL] [Abstract][Full Text] [Related]
42. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
43. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
44. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
[TBL] [Abstract][Full Text] [Related]
45. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
46. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus.
Kang I; Quan T; Nolasco H; Park SH; Hong MS; Crouch J; Pamer EG; Howe JG; Craft J
J Immunol; 2004 Jan; 172(2):1287-94. PubMed ID: 14707107
[TBL] [Abstract][Full Text] [Related]
47. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
[TBL] [Abstract][Full Text] [Related]
48. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
49. Immunodominant CD8 T cell response to Epstein-Barr virus.
Houssaint E; Saulquin X; Scotet E; Bonneville M
Biomed Pharmacother; 2001 Sep; 55(7):373-80. PubMed ID: 11669500
[TBL] [Abstract][Full Text] [Related]
50. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
51. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
52. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.
Mackay LK; Long HM; Brooks JM; Taylor GS; Leung CS; Chen A; Wang F; Rickinson AB
PLoS Pathog; 2009 Dec; 5(12):e1000699. PubMed ID: 20019813
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
54. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
55. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
Midgley RS; Bell AI; Yao QY; Croom-Carter D; Hislop AD; Whitney BM; Chan AT; Johnson PJ; Rickinson AB
J Virol; 2003 Nov; 77(21):11507-16. PubMed ID: 14557636
[TBL] [Abstract][Full Text] [Related]
56. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
[TBL] [Abstract][Full Text] [Related]
57. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
58. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
[TBL] [Abstract][Full Text] [Related]
59. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response.
Bell MJ; Brennan R; Miles JJ; Moss DJ; Burrows JM; Burrows SR
J Infect Dis; 2008 Jun; 197(11):1594-7. PubMed ID: 18419576
[TBL] [Abstract][Full Text] [Related]
60. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
